Published

SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of Hepatology
Date: 2026-05-01
Source: Crossref
DOI: 10.1016/s0168-8278(26)01861-1
PubMed: Unavailable

Authors

Signor Anna Colognesi Martina Finzi Giovanna Gabbia Daniela Mattarei Andrea Comai Stefano Pasut Gianfranco Folli Franco Manfredi Paolo De Martin Sara

Watch author

Derived topics and classifications

psilocybin Receptor Pharmacology Animal Study Animal Study

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models2026-05-01

Related papers

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto RatsPsychedelic Medicine · 2025-12-16 ‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injuryInternal Medicine Journal · 2026-01-01 Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive DisorderClinicalTrials.gov · 2025-05-14 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30 Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 StudyPsychedelic Medicine · 2026-01-18